To cite this article: Rietveld IM, Lijfering WM, le Cessie S, Bos MHA, Rosendaal FR, Reitsma PH, Cannegieter SC. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. J Thromb Haemost 2019; 17:
Introduction
The coagulation factors FI (fibrinogen), FII, FV, FVII, FVIII, FIX, FX, FXI and von Willebrand factor (VWF) play central roles in the initiation and propagation reactions of clot formation, and an imbalance in this complex reaction system can lead to venous thrombosis (VT). VT (the composite of deep vein thrombosis [DVT] and pulmonary embolism [PE] ) is a relatively common disease that annually affects 1-2 in 1000 people in developed countries [1] [2] [3] .
Over the past two decades, much progress has been made in understanding the pathophysiology of VT. It was discovered that elevated levels of most procoagulant factors (FII, FVII, FVIII, FIX, FX, FXI, fibrinogen, and VWF) are associated with an increased VT risk [4] [5] [6] [7] [8] [9] [10] . In contrast, high levels of FV, FXII and FXIII have not been clearly associated with VT [11, 12] . Previous studies evaluated only one or a few coagulation factors at a time. Furthermore, the limited size of earlier studies did not allow the determination of risk estimates at the extreme of the distribution (e.g. > 99th percentile).
Here, we extend previous studies that assessed the relationship between various coagulation factor levels and VT risk. We first explored a dose-response effect for FII, VII, VIII, IX, X, XI, fibrinogen and VWF in relation to the risk of VT up to very high levels. Next, we studied whether the relationship between high levels of some of these factors and VT risk was affected by the levels of other coagulation factors.
Methods
The Multiple Environmental and Genetic Assessment of risk factors for VT (MEGA) study is a population-based case-control study on risk factors for VT. Between March 1999 and September 2004, consecutive patients aged 18-70 years with a first objectively confirmed episode of DVT or PE were included from six participating anticoagulation clinics in the Netherlands. Information on the diagnostic procedure was obtained from hospital records and general practitioners. This study was approved by the Ethics Committee of the Leiden University Medical Center, and written informed consent was obtained from all participants. The investigation was conducted according to the principles expressed in the Declaration of Helsinki.
Study participants
Only patients with a diagnosis of VT that was confirmed with objective techniques were included in the analyses, as previously described [13] . Exclusion criteria were severe psychiatric problems and inability to speak Dutch. For logistic reasons, blood sampling was performed for participants included up to June 2002. In this period, 2377 patients provided a blood sample. Two sets of controls were gathered: partners of patients, and subjects from the general population reached by random-digit dialing (RDD) recruited from the same geographical area as the patients. One thousand four hundred and eighty-three participating partner controls (age < 70 years without VT) provided blood samples, and 1460 RDD controls (frequency matched to patients on age and sex) provided blood samples.
Laboratory assays
Approximately 3 months after discontinuation of oral anticoagulant therapy, patients and their partners were invited for collection of a blood sample. For patients who were still receiving anticoagulant therapy 1 year after the event, blood was drawn during anticoagulant therapy. All assays were performed by laboratory technicians who were unaware of the case-control status of the samples. Fibrinogen activity was measured on the STA-R analyzer according to the methods of Clauss. Prothrombin (FII), FVII, FVIII, FX and FXI activities were measured with a mechanical clot detection method on a STA-R analyzer, according to the manufacturer's instructions (Diagnostica Stago, Asni eres, France). FVIII antigen was measured with an in-house-developed sandwich ELISA with monoclonal IgG (CLB-117) as capture antibody, and horseradish peroxidase (HRP)-conjugated monoclonal IgG (CLB-A) as detection antibody, as described by Kamphuisen et al. [12] . FIX antigen was measured with an inhouse ELISA with rabbit anti-FIX antibodies and anti-FIX IgG conjugated to HRP (Dako A/S, Glostrup, Denmark), as described by Van Hylckama Vlieg et al. [7] . The presence of EDTA in the assay ensured the measurement of only the non-Ca 2+ -dependent conformation of FIX, so the results are not affected by the degree of c-carboxylation of FIX. VWF antigen was measured with the immunoturbidimetric method, by use of the STA Liatest kit (rabbit anti-human VWF antibodies), according to the manufacturer's instructions (Diagnostica Stago).
Statistical analysis
Blood samples were collected at least 3 months after the event took place, to exclude potential acute-phase reactions. To analyze whether such a phenomenon had nevertheless occurred, boxplots with medians and interquartile ranges for coagulation factors were constructed within the patient group at 3-6, 6-9, 9-12 and > 12 months of blood sampling after onset of VT, to study possible differences.
Odds ratios (ORs) and their 95% confidence intervals (CIs) as an estimate of the relative risk of VT for several coagulation factor levels were estimated and adjusted for age and sex (model 1) by the use of logistic regression. RDD subjects and partners of patients were pooled as one control group, as the mean values of coagulation factor levels in RDD and partner controls were similar (Table 1) . Cutoff points for coagulation factor levels were set at the 25th, 50th, 75th, 90th, 95th, 97.5th and 99th percentiles of antigen or activity levels in the control population, and entered into the model as categorical data. Individuals who were receiving anticoagulant treatment at time of blood collection were excluded from analyses of vitamin K-dependent coagulation factors (i.e. FII, FVII, FIX, and FX).
Because, in the control subjects, the highest measured level of each coagulation factor differs from those of the other coagulation factors, and this spread affects the previously determined cutoffs, we performed a sensitivity analysis in which the cutoffs were fixed strata based on absolute levels of measured coagulation factors (≤ 100, 101-110, 111-120, 121-130, 141-150, 151-160 and > 160 IU dL À1 ).
Next, in a mediation model, we aimed to study the relationship between one coagulation factor and VT via the inclusion of other coagulation factors (i.e. supposed mediators). For this purpose, we used the traditional approach to mediation analysis, which consists of comparing two regression models, one with and one without conditioning on the mediator (model 2) [14, 15] . However, we did not adjust FVIII for VWF or vice versa, because the levels of these factors are known to be closely related, in which case the errors in the measured levels play too large a role for precise conclusions to be drawn [16, 17] . Furthermore, we adjusted each factor for FVIII or VWF alone (model 3) or for all other factors except for FVIII and VWF (model 4). The correlation (r) between all coagulation factors was calculated.
To study the effects of external factors on the relationship between FVIIII levels and VT, we subsequently adjusted this relationship for body mass index (BMI) and major illness (defined as self-reported liver disease, kidney disease, rheumatoid arthritis, multiple sclerosis, heart failure, hemorrhagic stroke, arterial thrombosis, myocardial infarction, angina, ischemic stroke, peripheral vascular disease, and transient ischemic attack) and C-reactive protein (CRP). The relationship between FVIII levels and VT was also studied in various subgroups: provoked versus unprovoked, including a separate analysis with cases with VT after surgery, and DVT versus PE.
Statistical analyses were performed with SPSS for Windows, release 22.0 (SPSS, Chicago, IL, USA).
Results

General characteristics
The clinical characteristics of 5317 evaluable individuals (2377 cases and 2940 controls), of whom 47% were men, are summarized in Table 1 . The mean age at onset of VT was 48 years (range: 18-70 years). Two hundred and eighty-eight patients (12%) and 30 controls (1%) were receiving anticoagulant treatment at the time of venipuncture. Mean levels of all coagulation factors were higher in patients than in controls. No major differences in mean coagulation factor levels were observed when blood had been sampled within 3-6, 6-9, 9-12 or > 12 months after patients' first VT, indicating that coagulation factor levels were not affected by a temporary acute-phase reaction that was brought about by the thrombotic event ( Fig. 1) . Risk factors for VT were more frequently observed in cases than in controls. Major illnesses were present in both cases and controls, with, in general, there being more major illness in the cases, although the differences were small.
Risk estimates
In Table 2 , the relationship between coagulation factor levels and VT risk adjusted for age and sex (model 1) is shown. For all coagulation factors, a dose-response relationship was observed. The highest adjusted OR of 23.0 (95% CI 14.7-36.0) was observed for FVIII when individuals with the highest FVIII levels (> 266.2 IU dL À1 ; > 99th percentile) were compared with those in the lowest quartile (≤ 86.0 IU dL À1 ). Adjustment for BMI, major illness, and CRP, which is a marker for inflammatory processes, had limited effect (Table 3) . Similar risk estimates were obtained for FVIII activity levels (data not shown). High levels of all other tested coagulation factors were also associated with increased VT risk, albeit to a lesser extent. The maximum ORs for fibrinogen, FIX and FXI levels were between 3.5 and 4.0, and those for FII, FVII and FX levels were between 1.8 and 2.2. The coagulation factor levels were correlated with each other to different degrees (Table S1 ). The strongest correlation was found between FVIII and VWF levels (r = 0.811). Because FVIII and VWF levels are strongly correlated [16] , we repeated the analyses for VWF instead of FVIII. The relative risk estimate for high VWF levels (> 253 IU dL Table S2 ). A sensitivity analysis in which the cutoff values were based on absolute levels (≤ 100, 101-110, 111-120, 121-130, 141-150, 151-160 and > 160 IU dL À1 ), to rule out an effect of the variability of the spread within the coagulation factor levels, did not give different results: FVIII levels remained associated with a higher VT risk than levels of the other coagulation factors, and only FIX and FXI levels showed a slight remaining risk after adjustment for age, sex, and FVIII level (Table S3) . . Blood samples (number of samples mentioned per group) were collected via venipuncture 3-6, 6-9, 9-12 or > 12 months after onset of venous thrombosis. 514 (22) 748 ( 
Mediation analysis
Next, we adjusted each coagulation factor for all other measured coagulation factors (model 2). These adjusted risk estimates were lower for all coagulation factors than the risk estimates adjusted for age and sex only (model 1). For fibrinogen, FII, FVII and FX levels, they were reduced to unity, whereas an elevated risk remained for FVIII (OR 16.0; 95% CI 9.7-26.3), FIX (OR 1.7; 95% CI 1.0-2.9) and FXI (OR 1.9; 95% CI 1.1-3.4) levels when individuals with the highest levels (> 99th percentile; > 266.2, > 154 and > 154 IU dL À1 , respectively)
were compared with those in the lowest quartiles (≤ 86.0, ≤ 92 and ≤ 87 IU dL À1 , respectively). Exclusion of patients and controls who used vitamin K antagonists did not materially affect our results for VT risk.
To examine whether this decrease in thrombotic risk attributable to adjustment for all coagulation factors was mostly mediated by FVIII levels, i.e. the factor with the highest remaining risk after adjustment, all coagulation factors were next adjusted for FVIII alone (model 3). This resulted in a similar reduction in the ORs as when adjustment was performed for all coagulation factors (model 2), i.e. a reduction to unity for fibrinogen, FII, FVII and FX levels, and a slight remaining risk for FIX and FXI levels.
To complete the analysis, all coagulation factors were adjusted for the levels of all other coagulation factor except for FVIII (model 4). Whereas the risk estimates for FII, FVII and FX levels were again reduced to unity, the remaining risks for FIX, FXI and fibrinogen levels were higher than the ORs adjusted for FVIII alone (model 3).
When all these analysis were repeated with VWF instead of FVIII, similar results were obtained (Table S2) : the highest OR was found for VWF as compared with the other coagulation factors (model 1), which remained the highest after adjustment for all coagulation factors (model 2).
Analysis of FVIII in subgroups
In a subgroup analysis, we calculated VT risk according to FVIII levels in patients with unprovoked and provoked VT, in which we made a further distinction between provoked (all) and provoked by surgery only. The relative risks of increasing levels of FVIII for provoked VT (all) and unprovoked VT were similar. In patients who had provoked VT after surgery, lower relative risks were found with increasing levels of FVIII (Table 4) . Furthermore, we calculated the risk of DVT only, PE only, and PE combined with DVT ( Table 5 ). The relative risk for PE only was 15.0 (95% CI 8.6-26.1), that for DVT only was 27.8 (95% CI 16.9-45.8) and that for PE with DVT was 43.2 (95% CI 16.6-122.5) when the highest FVIII levels were compared with those in the reference group. CI, confidence interval; NA, not applicable; OR, odds ratio. Owing to a few missing measurements, the total might not add up to the target sum. *Adjusted for age and sex; model 1. †Adjusted for all other coagulation factors listed in Table 2 , and for age and sex; model 2. ‡Adjusted for FVIII antigen, age, and sex; model 3. §Adjusted for all other coagulation factors listed in Table 2 except for FVIII antigen, and adjusted for age and sex; model 4. ¶Excluding persons receiving anticoagulant therapy. 
Discussion
In this case-control study of nearly 2500 patients and 3000 controls, we determined the effects of increasing levels of FII, FVII, FVIII, FIX, FX, FXI, fibrinogen and VWF on VT risk. The relative risk estimates for all coagulation factors increased with increasing factor levels, with a maximum at the highest percentile cutoff levels (> 99th percentile of the control group). This suggests that there is not a threshold of factor levels at which the risk estimates do not further increase, making exact measurements of very high coagulation factor levels relevant for precise risk estimation. The relationships were not explained by age, sex, BMI, or major illness. Whereas the relative risk estimates were high for the highest FVIII, VWF, FIX, FXI and fibrinogen levels (i.e. > 99th versus ≤ 25th percentile; ORs of 23.0, 24.0, 4.0, 3.5, and 3.9, respectively), we observed only a weak association between high FII, FVII or FX levels and VT (i.e. ORs of 1.8-2.2). Our data confirm the results of previous studies, which found weak associations for FX (OR [6] , respectively). Differences in relative risk estimates for coagulation factors and VT between the literature and our present study can be explained by the choice of the reference group. In this study, we chose a reference group with low levels (i.e. a coagulation factor level that was < 25th percentile of normal) to analyze the presence of a dose-response effect, whereas other studies have chosen higher cutoffs, e.g. reference values that were at least 100 IU dL À1 or higher.
Further fine-tuning of the risk estimates by adjustment for all coagulation factor levels in a mediation model (model 2) resulted in attenuation, with the largest remaining risk for FVIII (OR 16.0; 95% CI 9.7-26.3; > 99th percentile versus ≤ 25th percentile) and VWF (OR 17.6; 95% CI 10.7-28.8; > 99th percentile versus ≤ 25th percentile) levels, some remaining risk elevation for high FIX and FXI levels, and a complete absence of associations for fibrinogen, FII, FVII and FX levels. These data demonstrate that only elevated FVIII, VWF, FIX and FXI levels are associated with VT when levels of other coagulation factors are taken into account. When all coagulation factors were adjusted for FVIII/ VWF alone (model 3), i.e. the coagulation factors with the strongest association with VT occurrence, similar ORs were found as after adjustment for all coagulation factor levels (model 2). This indicates that FVIII and VWF levels were the main contributors to the reduction in OR after adjustment for all coagulation factors. This is further underlined by the fact that the ORs adjusted for all coagulation factor levels except FVIII/VWF (model 4) were higher for FIX, FXI and fibrinogen levels than the risk estimates adjusted according to model 2 or model 3. This strong association of high FVIII or VWF levels with VT is in line with the findings that, after a first VT, patients are more prone to develop a second event with higher FVIII levels [18, 19] , and that patients with hemophilia A and von Willebrand disease, who have (very) low levels of FVIII or VWF, rarely suffer from VT. When episodes occur, they are mainly catheter-associated or occur shortly after therapy with FVIII, activated FVII, FEIBA or VWF concentrates [20, 21] . In a recent study, FVIII levels in hemophilia A patients were elevated after gene therapy [22] . This approach was successful for a prolonged period, in which levels of > 150 IU dL À1 were measured. Our data suggest that these individuals may have a higher risk of developing VT than before this treatment. In future experiments, this might be taken into account.
The findings of our study suggest that a common cause or mechanism increases the levels of various coagulation factors simultaneously, whereas only FVIII or VWF and, to a lesser extent, FIX and FXI are causally linked to VT (Fig. 2) . Theoretically, a common mechanism could simultaneously elevate the levels of various proteins by enhancing protein synthesis and/or secretion or by decreasing degradation. However, further research is necessary to determine how this common mechanism functions.
In this study, we observed a tight correlation between VWF and FVIII, as the two proteins increased VT risk in a similar manner. Consequently, an analysis in which all coagulation factor levels were adjusted for VWF level instead of FVIII level (model 2) produced a result similar to that following adjustment for FVIII level. The fact that FVIII and VWF circulate as a high-affinity non-covalent complex [16] , and are therefore considered as one entity, might explain the results of both analyses being similar.
In our study, we found a strong association between high FVIII and VWF levels and the risk of VT. We assume that the high FVIII levels directly lead to VT (Fig. 2) ; however, other scenarios are possible. The first is that, in patients with venous insufficiency, VWF, being released from the damaged endothelium, can result in an increased FVIII level. Venous insufficiency would then be the cause and VWF/FVIII the mediator of the resulting VT. Another scenario could be that VT leads to chronic venous insufficiency and a damaged endothelium, leading to high VWF/FVIII levels. In that scenario, high FVIII/ VWF levels would be the result of VT instead of being the cause or mediator of VT. As our study is a case-control study, we cannot distinguish these scenarios in an analysis. However, there are several reasons why we believe that a high VWF/FVIII has a direct causal effect: (i) blood group non-O (versus O) is related to higher FVIII levels and a higher VT risk [4, 23, 24] ; (ii) coagulation profiles (most likely including FVIII/VWF levels) stay stable over time [25] (as also indicated in Fig. 1) ; and (iii) an analysis in which we corrected for CRP, which is a marker for inflammatory processes, such as is present in venous insufficiency, did not affect the ORs of FVIII. This indicates that inflammatory events are most likely not responsible for the elevated levels of FVIII and VWF at the moment of blood draw. To study the exact relationships, other pathophysiological studies are required. We also studied the relationship between increasing FVIII levels and VT in separate subgroups. The relative risks were similar for patients with provoked and unprovoked VT. When provoked cases after surgery were considered separately, we observed that high FVIII levels were less strongly associated with surgery-related VT. Nevertheless, high FVIII levels were also more often present in patients with VT who had surgery than in controls. Distinct ORs were found for PE and DVT. This may indicate that FVIII levels play different roles in the etiology of PE and the etiology of DVT, which has been previously described for other risk factors for VT, such as FV Leiden. [26] However, as ORs are partly dependent on the underlying incidence, as we previously explained [26] , we cannot make a precise comparison between our subgroups, because we do not know the exact incidence rates of various subgroups, e.g. provoked VT by our definition or postsurgery.
There are a number of methodological aspects of this study that deserve comment. First, our study is a case-control study in which the blood sample was collected after the thrombotic event. Therefore, we cannot exclude the possibility that differences in plasma levels of the coagulation factors between patients and controls resulted from the thrombotic event itself. However, the blood draw was performed with a median of 10 months after the thrombotic event, and it is unlikely that the VT event had caused persistent abnormalities in coagulation factor levels [27, 28] . Indeed, no differences in coagulation factor levels were observed for patients from whom blood was drawn 3-6 months after their thrombotic event and those with a later blood draw (i.e. more than 6-9, 9-12 or 12 months). The effects of acute-phase reactions attributable to other events were not taken into account in this study, as the focus of the study was to investigate the relationship between increased coagulation factor levels and VT, and not the reasons for these increased levels.
Second, to exclude the possibility that anticoagulant therapy could affect the results, individuals who were still receiving anticoagulant therapy at the moment of venipuncture were excluded from analyses of vitamin Kdependent coagulation factors. Third, we did not have plasma samples available for all participating cases and controls. The reason for unavailability of a plasma sample may have been different between cases and controls. For cases, a reason for not visiting the research unit for a blood draw may have been severe illness. This would result in the effect sizes being probably underestimated, as increased levels of coagulation factors are associated with severe illnesses such as chronic heart disease or malignancy [29] [30] [31] .
To conclude, in this study, increased levels of all tested coagulation factors were associated with an increased VT risk, with FVIII and VWF levels being the strongest identified risk factors. The effects of all other coagulation factor levels were at least partially explained by FVIII and VWF levels. Our findings suggest that a common cause or mechanism increases the levels of various coagulation factors simultaneously, whereas only FVIII or VWF and, 
